Personalis (PSNL)
(Delayed Data from NSDQ)
$3.60 USD
+0.03 (0.84%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $3.68 +0.08 (2.22%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Personalis (PSNL) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$4.60 | $7.50 | $3.50 | 28.85% |
Price Target
Based on short-term price targets offered by five analysts, the average price target for Personalis comes to $4.60. The forecasts range from a low of $3.50 to a high of $7.50. The average price target represents an increase of 28.85% from the last closing price of $3.57.
Analyst Price Targets (5 )
Broker Rating
Personalis currently has an average brokerage recommendation (ABR) of 1.50 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 1.50 a month ago based on six recommendations.
Of the six recommendations deriving the current ABR, four are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 66.67% and 16.67% of all recommendations. A month ago, Strong Buy made up 66.67%, while Buy represented 16.67%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/PSNL.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 4 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/9/2024 | H.C. Wainwright & Co. | Swayampakula Ramakanth | Strong Buy | Strong Buy |
4/30/2024 | Lake Street Capital Markets | Thomas Flaten | Not Available | Strong Buy |
4/11/2024 | Needham & Company | Michael Matson | Moderate Buy | Moderate Buy |
4/1/2024 | Cowen & Co. | Daniel Brennan | Strong Buy | Strong Buy |
1/7/2024 | BTIG | Mark Massaro | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.50 |
ABR (Last week) | 1.50 |
# of Recs in ABR | 6 |
Average Target Price | $4.60 |
LT Growth Rate | NA |
Industry | Medical - Generic Drugs |
Industry Rank by ABR | 71 of 253 |
Current Quarter EPS Est: | -0.34 |